![Michelle Parker](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 2 M $ al 31/07/2026
Michelle Parker is currently the Chief Executive Officer & Director at Clarity Pharmaceuticals Ltd. She previously worked as the Head-International Clinical Research Operations at Novartis Australia Pty Ltd. Ms. Parker completed her undergraduate degree at The University of Sydney.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 20/04/2026 | 1.013.000 ( 0,27 % ) | 2 M $ | 31/07/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| CLARITY PHARMACEUTICALS LTD | Director Ejecutivo | 11/10/2024 |
| Empresas | Cargo | Fin |
|---|---|---|
Novartis Australia Pty Ltd.
 Novartis Australia Pty Ltd. BiotechnologyHealth Technology Manufactures biological products | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 3 |
|---|---|
The University of Sydney
 The University of Sydney Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Australia Pty Ltd.
Novartis Australia Pty Ltd. BiotechnologyHealth Technology Manufactures biological products | Health Technology |
Clarity Pharmaceuticals Ltd.
 Clarity Pharmaceuticals Ltd. Medical SpecialtiesHealth Technology Develops radiopharmaceutical products | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
